Anticancer Therapies – News and Features

A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.

A genomic tug of war for a gene activator could explain why some cancers respond to decitabine and others don't respond or become resistant over time.

A lesser-known DNA repair pathway that is upregulated in breast, ovarian and prostate cancer has been pieced together and laid out step by step in a new paper.

Macrophages, a type of white blood cell that can destroy invading pathogens, have an innate ability to infiltrate tumor cells, making them a potentially important tool in treatments that use transplanted cells to fight disease, known as cell therapy.

Researchers have identified the genetic changes that occur during pancreatic cancer metastasis and have found a drug to disrupt the process.

A study of newly created databases of medulloblastoma has found that patients with tumors containing circular extrachromosomal DNA are twice as likely to relapse and three times as likely to die within five years of diagnosis.

Disrupting one gene in CAR T cells used for cancer therapy makes them more potent and able to fight the cancer for longer, reports a new study.

A small molecule drug, one of 27 million screened in a library of potential new drugs, has shown promise as a painkiller, outperforming gabapentin for treating four types of chronic pain.

Cancer stem cells cause the aging of macrophages in mice with healthy immune systems, creating conditions for the formation of tumors.

A model based on artificial intelligence is able to predict the therapy outcome in 80% of ovarian cancer patients. The tool, named IRON (Integrated Radiogenomics for Ovarian Neoadjuvant therapy), analyzes various patient clinical features.